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Abstract: Basic Helix-loop-Helix (bHLH) factors play a significant role in both development and disease. bHLH factors 
function as protein dimers where two bHLH factors compose an active transcriptional complex. In various species, the 
bHLH factor Twist has been shown to play critical roles in diverse developmental systems such as mesoderm formation, 
neurogenesis, myogenesis, and neural crest cell migration and differentiation. Pathologically, Twist1 is a master regulator 
of epithelial-to-mesenchymal transition (EMT) and is causative of the autosomal-dominant human disease Saethre 
Chotzen Syndrome (SCS). Given the wide spectrum of Twist1 expression in the developing embryo and the diverse roles 
it plays within these forming tissues, the question of how Twist1 fills some of these specific roles has been largely unan-
swered. Recent work has shown that Twist’s biological function can be regulated by its partner choice within a given cell. 
Our work has identified a phosphoregulatory circuit where phosphorylation of key residues within the bHLH domain al-
ters partner affinities for Twist1; and more recently, we show that the DNA binding affinity of the complexes that do form 
is affected in a cis-element dependent manner. Such perturbations are complex as they not only affect direct transcrip-
tional programs of Twist1, but they indirectly affect the transcriptional outcomes of any bHLH factor that can dimerize 
with Twist1. Thus, the resulting lineage-restricted cell fate defects are a combination of loss-of-function and gain-of-
function events. Relating the observed phenotypes of defective Twist function with this complex regulatory mechanism 
will add insight into our understanding of the critical functions of this complex transcription factor.  
Keywords: Twist1, bHLH, transcription, dimerization, DNA binding, Saethre Chotzen Syndrome, limb development, 
phosphorylation. 
THE BASIC HELIX LOOP HELIX PROTEIN 
The bHLH domain is an evolutionarily conserved motif 
that is well represented from humans to flatworms. The 
bHLH domain consists of a short stretch of basic amino 
acids followed by an amphipathic -helix, a loop of varying 
length and then another amphipathic -helix (for detailed 
review see [1]). Each of the -helices allows for protein-
protein interactions with other bHLH proteins. The result of 
dimerization is the juxtaposition of the basic domains creat-
ing a combined DNA binding motif that in the majority of 
proteins allows for binding to a canonical sequence termed 
an E-box (CANNTG) [1]. Although HLH proteins can be 
classified into 5-subclasses, it is convenient to generalize 
categorization into 3 major classes: ubiquitously expressed 
bHLH factors (E-proteins Class A); tissue specific/restricted 
bHLH factors (Class B); and the negative regulatory HLH Id 
factors, which lack a basic DNA binding domain thereby 
sequestering E-proteins from forming functional transcrip-
tional complexes [1]. Through the study of the Class B myo-
genic bHLH factors, it was established that these proteins 
could drive skeletal muscle specification and differentiation 
via heterodimer formation with bHLH factors from Class A 
[2-4]. Moreover, Id class HLH factors could compete for E-
proteins as dimer partners adding a critical regulatory input 
to the system. As additional class B proteins were discov-
ered, this regulatory model was initially applied; however, it 
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TWIST A bHLH FACTOR REQUIRED FOR MESO-
DERM FORMATION  
In the fly, Twist was identified as a critical factor for the 
onset of gastrulation and the formation of mesoderm [5-7]. 
Regulated in part by Dorsal, Twist and the Zn-finger factor 
Snail coordinate with Dorsal to specify mesoderm in the fly. 
Mechanistically, it was presumed that Twist required a dimer 
partner from Class A to regulate gene expression [7]; how-
ever, in contrast to the established mechanism for the myo-
genic bHLH factors, Twist appeared capable of functioning 
as a homodimer. In elegant work from the Baylies labora-
tory, they showed that Twist conveyed different biological 
functions depending on the dimer partner choice. Using a 
tethered dimer approach to link Twist to itself or to 
Daughterless (the Class A E-protein in fly) via a short gly-
cine linker sequence, the function of specific Twist dimer 
complexes were assayed. Expression of Twist-Twist ho-
modimers in the fly resulted in mesoderm specification such 
that ectopic expression led to the formation of somatic mus-
cle in inappropriate locations [7]. Moreover homodimer 
expression can rescue the early gastrulation defects in Twist 
mutant files. In contrast, Twist-Daughterless heterodimers 
antagonize mesoderm gene expression and genetic interac-
tions show a complex gene dosage relationship [7]. These 
studies were the first to demonstrate that Class B bHLH 
factors could partner with a non-E-protein partner and facili-
tated a better understanding of the role played by one the 
vertebrate orthologs of Twist: Twist1. These studies also beg 
the question, how is dimer choice controlled? 
TWIST1 REGULATES MESENCHYMAL CELLS 
POPULATIONS IN MICE 
Evolutionary conservation of critical proteins is well es-
tablished between species. Given the importance of Twist in 2642    Current Medicinal Chemistry,  2008 Vol. 15, No. 25  Firulli and Conway 
the fly, it seems logical that Twist orthologs would play 
equally important roles in higher organisms. Indeed, the 
identification of Twist-related factors shows the representa-
tion in higher species as well as in early organisms such as 
C. elegans and in mammals there are six Twist orthologs 
(Twist1, Twist2, Hand1, Hand2, Paraxis, and Scleraxis) [8-
14] (Fig. 1).  
In mouse, Twist1 function was directly assessed by gene 
deletion [15]. Twist1 null embryos die around E11.5 and 
display a number of defects that reflect a functional role in 
mesenchymal cell populations. Major phenotypes include 
exencephaly, hypoplastic limb buds, and vascular defects 
[15] (Fig. 1). These defects correlate to tissues that require 
cranial neural crest cells (NCC) to emigrate and contribute to 
the effected tissue [15, 16]. Our own data further shows that 
Twist1 also plays a role in mediating outflow track (OFT) 
cushion formation within the developing heart and that the 
defects observed in Twist1 null OFTs result from defects in 
cardiac NCC cell behavior [17]. Recently, a conditional null 
Twist1 allele has been reported and the use of this mouse 
model in looking at tissue-specific Cre deletions will shed 
additional light on all of the lineages that contribute to these 
phenotypes [18].  
Twist1 heterozygote null mice display a number of phe-
notypes including dysmorphic facial features and preaxial 
polydactyly in a partially penetrant fashion. Presentation of 
these phenotypes is dependent on mouse background and fits 





























Fig. (1). Regulatory conservation of Twist-family bHLH factors . Top shows amino acid alignment of human TWIST1 with murine protein 
family members Twist2, Hand1 and 2, Paraxis and Scleraxis. The conservation of the phosphoregulated threonine (T) and serine (S) is noted 
by black shading. Conservation is maintained back to invertebrates [25]. Red-bolded residues shown in the human sequence identify specific 
point mutations found within SCS patients. Middle panels show a wildtype and Twist1 null embryo at time of death E11.5. Note the pro-
nounced exencephaly (white arrowhead), hypoplastic limb buds (lb), and reduced lateral mesoderm (lm). Bottom shows the phosphoregula-
tory circuit that governs Twist-family dimer control and DNA binding. PKA is capable of phosphorylation Twist1 whereas only PP2A com-
plexes containing B56 can specifically dephosphorylate the helix I resides. Phosphoregulation of Twist1 Provides a Mechanism  Current Medicinal Chemistry,  2008 Vol. 15, No. 25      2643 
Twist. Interestingly, these haploinsufficient phenotypes are 
similar to an autosomal dominant, haploinsufficient disease 
in humans called Saethre Chotzen Syndrome (SCS). Not 
coincidently, a high percentage of SCS patients have null, 
mis-sense or non-sense mutations in TWIST1 (see section 
below). 
TWIST1 AND SAETHRE CHOTZEN SYNDROME 
SCS (OMIM101400) affects between 1-25,000 to 1-
65,000 live births (for detailed review [19]). Amongst the 
phenotypic traits of SCS patients are craniosynostosis, low 
frontal hairline, facial asymmetry, and eyelid ptosis. Limb 
defects are also observed and include polydactyly, brachy-
dactyly and syndactyly [20]. Although SCS can result from 
gene mutations in other factors, such as Snail [21, 22], the 
majority of documented SCS cases show a loss-of-function 
mutation in the human TWIST gene. Identification of TWIST 
was facilitated by the observations made in regards to the 
phenotypic similarities between SCS and Twist1 heterozy-
gous null mice as well as the fact that data shows SCS maps 
to 7p21-p22, which is homologous to mouse chromosome 12 
region BC1, the location of Twist1 [19]. To date, 73 known 
mutations in TWIST have been identified in SCS patients and 
although a number of these mutations involve large dele-
tions, a number of mutations are point mutations that cluster 
near the basic DNA-binding domain. Initial presumption was 
that these mutants would affect DNA binding; however, 
DNA binding of this subset of TWIST1 SCS alleles was 
subsequently established [11].  
In the study of the Twist1-related proteins Hand1 and 
Hand2, it was also observed that these factors could form 
and function as non-E-protein dimers [23, 24]. Given that it 
was well established that Hand1 and Hand2 could and did 
function as heterodimers with E-proteins, the idea that ho-
modimers could also convey biological function requires that 
dimer choice must be a regulated process. In an effort to 
determine how Hand dimer regulation was controlled, we 
uncovered a phosphoregulatory circuit involving protein 
kinase A (PKA) or PKC and the trimetric protein phospha-
tase 2A (PP2A) containing the B56 regulatory subunit 
which could phosphorylate-dephosphorylate both Hand1 and 
Hand2 on a serine and threonine just carboxy to the basic 
domain [25] (Fig. 1). Studies using phospho-deficient and 
phosphorylation mimic forms of Hand1 showed that chang-
ing the charge of helix 1 was sufficient to alter Hand1 affini-
ties for its possible bHLH dimer partners. Moreover, when 
these Hand1 point mutants were ectopically expressed in 
vivo, distinct limb phenotypes were obtained [25] (Fig. 2). 
Upon closer examination of the evolutionary conservation of 
these residues within the Twist-family, it was quickly deter-
mined that these residues were conserved in all Twist family 
members as far back as Drosophila [26]. When TWIST SCS 
alleles displaying point mutations within the basic domain 
were compared to the wild type TWIST allele, it was found 
that these mutants did disrupt the consensus PKA site. 
Moreover, we noted that a TWIST1 mutation at S123 (rela-
tive to the human sequence) was sufficient to cause SCS and 
this residue was identical to the phosphoregulated serine in 
both Hand1 and Hand2 [26] (Fig. 1). 
ALTERED PHOSPHOREGULATION OF TWIST1 
CAN CAUSE SCS 
Work done by a number of groups showed that ectopic 
expression of Hand2 within the developing limbs in both 
mice and chick results in preaxial polydactyly [27, 28]. 
Hand2 is expressed within the developing limb buds and is 
associated with an auto-regulation loop with the morphogen 
Sonic hedgehog (shh). Shh expression within the limb in part 
defines the zone of polarizing activity (ZPA), which imparts 
positional identity to the forming hand. Hand2 over expres-
sion expands expression of Shh resulting in ectopic ZPA 
formation and thus extra digits [27, 28]. Interestingly, Twist1 
haploinsufficiency phenocopies the Hand2 gain-of-function 
phenotype suggesting that gene dosage and possible func-
tional interactions between Twist1 and Hand2 are critical for 
modulating digit positional identity.  
Indeed validating this hypothesis, dimer interactions be-
tween Twist1 and Hand2 can occur in vivo and partial coex-
pression within the developing limb, confirms biological 
relevance to the observed Twist1-Hand2 dimer formation 
[26]. To directly investigate if phosphoregulation of Twist1 
modulated Twist1 dimer choice, Fluorescence Resonance 
Energy Transfer (FRET) [29] was used to assay dimer inter-
action strength of Twist1 with itself, ubiquitous E12, and 
Hand2 [26]. Results of these studies show that wild type and 
phosphorylation mimic Twist1 displayed similar affinities 
for itself, E12 and Hand2 albeit at altered interaction 
strengths [26]. In contrast, the Twist1 hypophosphorylation 
mutant (which models an established SCS TWIST1 allele) 
showed a distinct dimer affinity profile from the wild type 
protein, suggesting that TWIST1 dimer choice within a cell 
would be different dependent upon phosphorylation state 
[26]. Given that hypophosphorylated Twist1 displayed al-
tered dimerization characteristics from wild type Twist1, 
phosphorylation analysis of the basic domain TWIST1 SCS 
alleles was undertaken. As predicted, these mutations 
showed a decreased ability to be phosphorylated by PKA in 
vivo supporting the idea that phosphoregulation of these 
evolutionarily conserved threonine and serine residues can 
modulate the biological activity of Twist1 [26]. Considering 
that 5 independent Twist1 SCS point mutations encode pro-
teins with a reduced ability to be phosphorylated and that 
hypophosphorylated Twist1 displays distinct preferences for 
various bHLH partners, the idea that this molecular switch 
modulates Twist1 function is appealing.  
TWIST1 AND HAND2 DISPLAY ANTAGONISTIC 
FUNCTION IN THE LIMB 
In examining the Twist1 FRET interaction data, the in-
teractions with Hand2 are most divergent. For instance, wild-
type Twist1 has the highest interaction affinity for Hand2, 
whereas the SCS helix 1 hypophosphorylation Twist1 mu-
tant has the lowest affinity for Hand2 dimerization [26]. This 
observation, in addition to the observation that Twist1 loss-
of-function phenocopies Hand2 gain-of-function in regards 
to polydactyly, led us to conduct a genetic test of this intrigu-
ing biochemical model. The experiment was a simple inter-
cross of a Hand2 null allele onto a Twist1 haploinsufficient 
background, thus taking what was effectively a Hand2 gain-2644    Current Medicinal Chemistry,  2008 Vol. 15, No. 25  Firulli and Conway 
of-function (2 Hand2 alleles to 1 Twist1 allele) and rebalanc-
ing the gene dosage to one copy of each bHLH partner. The 
results of this experiment show a complete rescue of poly-
dactyly on the Twist1 heterozygous background [26]. In 
similar studies in the chick using retrovirus over expression, 
Hand2 expression results in polydactyly, which can be par-
tially rescued via coexpression of retrovirus expressing wild-
type Twist1. In contrast, coexpression of a SCS helix 1 hy-
pophosphorylation  Twist1 mutant retrovirus fails to rescue 
Hand2 generated polydactyly [26]. These findings support 
the hypothesis that Twist1 dimer choice is regulated by the 
actions of PKA and B56-containing PP2A and can convey a 
distinct biological function to Twist1. As these residues are 
also conserved in Drosophila, Twist phosphoregulation 
likely controls dimer choice in this genetic model system.  
Interpretations are complicated when partner choice has 
many inputs: how do you interpret results and what is the 
best experiment? 
What is still not clear from this data is the identity of the 
specific dimer pairs that are regulating specific molecular 
programs. Within a given cell, multiple bHLH and HLH 
factors are coexpressed temporally and in a dynamic fashion. 
The obvious changes in stoichiometry by altering ratios of 
any bHLH protein will affect the availability of E12 and 
other factors that can find each other and dimerize. The ex-
pression of Id factors further complicates this relationship as 
Id factors can titrate available E-proteins levels directly. By 
this logic, over expression of bHLH factors must be viewed 
in a different light. Swamping a cell with many more copies 
of one factor will undoubtedly result in E-protein titration, 
unintended bHLH heterodimers, and over expressed ho-
modimers that will collectively orchestrate many of the re-
sultant phenotypes. Even in “simple” gene knockout studies, 
the removal of a bHLH transcription factor will clearly result 
in the loss of regulation of downstream target genes; addi-
tionally, the dimer pools within the cell will be altered allow-
ing for the formation of a new dimer pool that will contain 
bHLH complexes that would not normally form and thus 
modulate gene expression in unintended ways. Simply put, 
any gene knockout of a factor that requires a partner for 
biological activity is very likely to exhibit phenotypes that 
include direct loss-of-function and deleterious gain-of-
function mechanisms. This is exemplified by the observation 
that Twist1-Hand2 double heterozygous null mice are more 
phenotypically normal than mice heterozygote for only 
Twist1.  
As Fig. (3) schematizes, the balance between Twist1 and 
Hand2 within the developing limb is critical for normal 





















Fig. (2). Model of Twist–family bHLH protein dimer regulation. Twist-family proteins have been shown to exhibit promiscuous dimeriza-
tion characteristics that allow for multiple functional partners. In addition to expression levels of bHLH proteins within a cell as well as E-
protein titration via Id factors, the phosphorylation state modulates Twist-family protein dimer affinities for its available partners thereby 
driving biological function. Expression of hypophosphorylation or phosphorylation mimic forms of the protein conveys distinct phenotypes 
in vivo.  
(Fig. (2) adapted from [24]
 PKA, PKC, and the Protein Phosphatase 2A Influence HAND Factor Function: A Mechanism for Tissue-Specific 
Transcriptional Regulation © 2003 with permission from Elsevier). Phosphoregulation of Twist1 Provides a Mechanism  Current Medicinal Chemistry,  2008 Vol. 15, No. 25      2645 
ences this relationship, thus an increase in Hand2 relative to 
Twist1 results in polydactyly. Would the gene dosage ma-
nipulation work in the opposite direction? That is, would 
having more Twist1 relative to Hand2 also produce abnormal 
development? In gain-of-function experiments, wild type, 
hypophosphorylation and phosphorylation mimic forms of 
Twist1 were expressed within the developing limbs of mice 
using the limb specific Prx1 promoter [30]. Results show 
that Twist1 gain-of-function resulted in medial defects 
within both the fore- and hindlimbs; however, as predicted 
by the gene dosage model, no polydactyly was observed. 
What was observed is that the phosphorylation mutants dis-
play unique phenotypes. Consistent with Twist1T125; 
S127A being an SCS allele, it shows a less severe phenotype 
then wildtype Twist1 [30]. Given that hypophosphorylated 
Twist1 shows a reduced antagonism for Hand2, this data fits 
the model well. Interestingly, the Twist1 phosphorylation 
mimic shows the most dramatic limb phenotypes including a 
severe reduction in ossification and medial limb structures; 
but again, no polydactyly was observed. Clearly, Twist1 
gain-of function is mediating limb defects that are distinct 
from those of Hand2 gain-of-function. 
One must consider that these are gross over expression 
experiments and given that the presumed mechanism is di-
mer formation, we cannot account for the deleterious titra-
tion of endogenous bHLH factors that would result in their 
altered function. One obvious solution to decoding the 
mechanism underlying these observed phenotypes is to em-
ploy the experimental approach used in the study of droso-
phila twist and employ tethered dimers to look at direct 
downstream effects. Mouse Twist1 tethered proteins bind 
DNA and transactivate promoters in a manner similar to 
when Twist and E12 are expressed as separate polypeptides 
[30, 31]. When expressed in the developing limb, distinct 
phenotypes for Twist1-Twist1 homodimers, Twist1-E12, and 
Twist1-Hand2 heterodimers are observed and those pheno-
types correlate well with the phenotypes observed by the 
expression of the monomeric wild type and mutant Twist1 
proteins [30]. Interestingly, the expression of Twist1 ho-
modimers displayed similar limb phenotypes to those ob-
served by the expression of the Twist1 phosphorylation 
mimic. Twist1-E12 tethered dimers show similar defects as 
those exhibited by the expression of wildtype Twist1. Most 
surprisingly, Twist1-Hand2 tethered complexes showed 
polydactyly and a mild loss of some medial structure; a 
combinatorial effect supporting the possibility of more then 
antagonistic functions in the limb program. Although the 
phenotypes are clearly not identical, the differences observed 
between the monomeric and tethered dimer data likely re-
flect the effect of endogenous bHLH factor titration from 
monomer over expression that will not occur when using a 
tethered dimer pair. 
To complicate the mechanism still further, it has also 
been shown in the monomeric analysis that phosphoregula-
tion of Twist1 influences its affinity for E-boxes in a cis-
element dependent manner [30]. Thus in addition to dimer 
choice, phosphorylation influences which E-box elements 
that the Twist1-containing bHLH complexes will bind. In 
combination with chromatin remodeling, which is the ulti-
mate dictator of transcription factor accessibility, a highly 
regulated scheme emerges where the overall level of bHLH 
expression within a cell, combined with the phosphoregula-
tion of the Twist bHLH family members will define a Twist-































Fig. (3). Gene balance model between Twist1 and Hand2 in the 
developing limb. Left shows genotypes that convey Twist1 hap-
loinsufficiency resulting in polydactyly where as genotypes to the 
right convey normal limb development. Of note, point mutations 
that disrupt phosphorylation (Twist1T125;S127A: TW1AA) of 
Twist1 result in phenotypes indistinguishable from a genetic im-
balance with Hand2.  Below is an E17.5 day transgenic mouse 
embryo expressing Hand2 via  the Prx1-limb-specific promoter. 
Obvious is right forepaw polydactyly with left forepaw showing 
normal digit formation. Given that Prx1-expression via this pro-
moter fragment is not asymmetric [31], this example shows the 
critical balance of Twist-Hand2 gene dosage as subtle differences 
in expression between left and right limbs within the same animal 
can result in different phenotypes. 2646    Current Medicinal Chemistry,  2008 Vol. 15, No. 25  Firulli and Conway 
drive transcriptional programs based on the ability of the 
Twist dimers formed to access compatible cis-elements 
available for interaction. Id factors, which will independently 
influence the amount of E-protein available, also convey 
dimer choice by a simple swing of mass action. Thus, am-
phipathic protein structures need to interact to be stable in an 
aqueous environment and a dramatic change in the access of 
one will greatly influence the interactions of the others. 
It is interesting to consider how sensitive biological pro-
grams are to this elaborate regulatory mechanism. How 
many molecules of one factor vs. another will tip the balance 
between modulating normal vs. abnormal gene expression? 
How much do post-translational modifications modulate this 
critical dosage? Although we cannot yet answer these ques-
tions, we can see examples within the same animal where 
such issues must be at play. For example, the Hand2 trans-
genic shown in Fig. (3) displays asymmetrical polydactyly 
despite the observation that the Prx1-promoter does not 
show asymmetrical expression levels between left and right 
[32]. Does this result reflect a threshold of Hand2 expression 
that was reached in one but not the opposing limb and/or a 
variation in phosphorylation state of either Twist1 or Hand2 
at a critical point in development? Addressing these ques-
tions would require more elegant in vivo and in vitro experi-
mental systems and analysis. To avoid issues of over expres-
sion, direct helix I point mutant knockins for both Twist1 and 
Hand2 would allow for a better assessment of gene dosage 
within the tissues that need to specifically express these 
factors. Although tethered dimer knockin animal models 
would be more artificial, the use of a conditional activation 
allele expressing such a tethered complex could add valuable 
insight within specific developmental windows that would 
lead to a better understanding of the role that Twist1 plays 
within the mesenchymal cell populations that allow for the 
complex body structure in multi-cellular organisms. 
TWIST AND CANCER 
In addition to its essential role in modulating the behavior 
of mesenchymal cell populations critical for development, 
Twist1 is also an oncogene and is associated with a number 
of aggressive neoplasias including gastric, liver and most 
notably breast cancers [33-38]. The oncogenic role of Twist1 
is not in facilitating cell transformation but rather it facili-
tates the ability of the cells within a primary tumor to un-
dergo a pathological EMT similar to its function in develop-
ment. EMT allows tumor cells to migrate away from the 
primary tumor, enter the lymphatic system, and settle into 
secondary tumor sites or metastasis [37]. Using a mouse 
mammary tumor model, Yang and colleagues made use of 4 
tumor cell lines isolated from the same mammary tumor that 
displayed distinct abilities to promote metastasis in mice. 
Subtractive screens identified Twist1 expression as being a 
predictor of metastaic behavior and the study goes on to 
show that the most aggressive metastaic cell line could be 
rendered non-metastaic by siRNA knockdown of Twist1 
expression [37]. Conversely, using a gain-of-function ap-
proach they show that expression of Twist1 in epithelial cell 
lines drives EMT making the cells mesenchymal in pheno-
type [37]. Taken together, this data suggests Twist1 as a 
master regulator of EMT. In the developing embryo it allows 
for cell migration programs critical for normal body pattern-
ing; whereas in cancer, it allows for secondary tumor forma-
tion, which is the ultimate cause of mortality.  
FUTURE DIRECTIONS 
The pivotal role that Twist1 plays in both embryonic de-
velopment and disease is well established. In both of these 
roles, the biological function of Twist1 within mesenchymal 
cell populations is obvious. In comparison to the remaining 
Twist-family members, other then loss-of-function pheno-
types resulting from targeted gene deletion, Twist1 is the 
only protein within the family that displays dominant disease 
phenotypes. It is likely that other family members play criti-
cal roles in utero and the lack of evidence for these factors 
contributing to postnatal disease may reflect phenotypes that 
result in early embryonic death. Suspiciously, all family 
members are expressed within tissues that undergo morphol-
ogy changes. Has gene expansion through evolution allowed 
for more specialized functions regulating cell shape and 
behavior? Currently this is our favorite hypothesis, which we 
are in the process of testing. Point mutant knockins for the 
various Twist-family members are underway and should 
shed insight into such cell behavior. 
Of note, when considering the role of Twist1 in cancer 
progression, is the observation that although Twist1 appears 
necessary for metastasis in the mouse breast cancer model, it 
is probably not sufficient given that 3 of the 4 cell lines ex-
press comparable levels of Twist1 protein yet 2 of the 3 cell 
lines are largely non-metastatic [36]. Given that Twist1 pro-
tein levels are similar yet metastatic behavior is different, an 
additional component to Twist1 functional regulation must 
be required for metastasis. It will be interesting to investigate 
the role of Twist1 phosphoregulation in the process of tumor 
progression thus linking the elaborate control of dimer 
choice and DNA binding preferences to neoplastic disease. 
In support of this hypothesis, PP2A, has recently been identi-
fied as a tumor suppressor [39] and B56 containing PP2A 
complexes could play a role in regulating Twist1 function in 
cancer via control of the phosphorylation state of Twist1. If 
Twist1 regulation via  phosphorylation is indeed a critical 
component of tumor progression, it will provide a potential 
therapeutic target to inhibit EMT thereby reducing the inci-
dence of lethal pathologies. Further investigations into gain-
ing a better understanding of the Twist-family functional 
mechanism will likely add valuable insights into the roles 
that this transcription factor family plays in development and 
disease. 
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